Merck Appoints Maya Martinez-Davis as Global Head of Oncology
Merck announces the appointment of Maya Martinez-Davis (46), as Global Head of oncology Franchise for its biopharma business. She will report to Rehan Verjee, Chief Marketing and Strategy Officer of Merck’s Healthcare business sector, and will be based in Billerica, Massachusetts, USA.

Maya Martinez-Davis
Merck KGaA
In her new role leading the Global Oncology Franchise, Martinez-Davis’ responsibilities will include defining integrated global oncology strategies, and delivery of therapeutic launches, starting with Avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck, and currently managed under a strategic alliance with Pfizer. The first potential commercial launch for Avelumab is expected in 2017.
Prior to joining Merck, Martinez-Davis was a senior executive with Pfizer for more than a decade, delivering on therapeutic area portfolio strategies, in-market growth strategies, and major launches. Prior to her tenure with Pfizer, she held senior-level and director-level positions with Aventis Pharma in oncology.
Martinez-Davis assumes the role of her predecessor, Andrew Schiermeier.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.